1.
VENTAVIS® (iloprost) full Prescribing Information. Actelion Pharmaceuticals US, Inc., November 2013.
2.
Denyer J, Nikander K, Smith NJ. Adaptive Aerosol Delivery (AAD) technology. Expert Opin Drug Deliv. 2004;1:165-176.
3.
Hardaker LE, Hatley RH. In vitro characterization of the I-neb Adaptive Aerosol Delivery (AAD) System. J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 1):S11-S20.
4.
Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329.
5.
Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension. The clinical syndrome. Circ Res. 2014;115:115-130.
6.
Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925-1932.
7.
Badesch DB, McLaughlin W, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:56-61.
8.
Giald A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
9.
Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol. 1999;61:391-415.
10.
Vane JR, Bottlin RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol. 1995;75:3A-10A.
11.
McLaughlin VV, Shah SJ, Souza R, et al. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65:1977-1997.
12.
Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010;104(1)9-21.
13.
Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol. 2002;26:194-201.
14.
Data on file, Actelion Pharmaceuticals.
15.
McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257-1263.
16.
Nikander K, Denyer J. Adaptive Aerosol Delivery (AAD) technology. In: Rathbone MJ, Hadgraft J, Roberts MS, eds. Modified-Release Drug Delivery Technology. New York, NY: Marcel Dekker, Inc. February 2011.
17.
Olschewski H, Rohde B, Berhr J, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest. 2003;124;1294-1304.
18.
Van Dyke RE, Nikander K. Delivery of iloprost inhalation solution with the Halolite, Prodose, and I-neb Adaptive Aerosol Delivery systems: an in vitro study. Respir Care. 2007;52:184-190.
19.
Simonneau G, Gatzoulis MA, Adatia A, et al. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol. 2013; 62(25 suppl D): D34-D41.
20.
Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130:2189-2208.
21.
Beghetti M, Reber G, de Moerloose P, et al. Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur Respir J. 2002;19:518-524.
22.
Food and Drug Administration. Ventavis (iloprost) Inhalation Solution NDA 21-779. Medical Review(s). Jun 30 2004. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-779_Ventavis_medr.pdf.
23.
Philips Respironics Respiratory Drug Delivery (UK) LTD. I-neb AAD System Clinician's Training Manual. Chichester, UK: Philips Home Healthcare Solutions; August 3, 2012. 1040847, issue 3.
24.
Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: AACP evidence-based clinical practice guidelines. Chest. 2004;126(suppl):7S-10S.